Latest Chinese Healthcare Reform Release Offers Little Change
This article was originally published in PharmAsia News
According to an industry insider privy to China's healthcare reform draft soliciting the latest round of public opinion (PharmAsia News, Sep.15, 2008), the overall plan does not differ much from the previous version in terms of new concepts or changes. It seems to hammer together hodge-podge proposals from various organizations, with little specifics on execution and operation. Although the reform seeks to resolve the problem of "medical care sustained by drug income" through separate management of hospitals' income and expenses, the strategy does not address the fundamental issues. Current media only cover small portions of the entire plan as the opinion soliciting period will only be closed in about a month's time. (Click here for more - Chinese Language)
You may also be interested in...
China's State Council has decided to solicit public opinion again to deepen its health care reform proposal. The draft spells out the reform's direction, objective, principles and key measures, with the overall goal of building up the basic healthcare system to cover both urban and rural residents by 2020. In the near term, the government will focus on five areas: (1) speeding up the guaranteed coverage of healthcare; (2) building a national basic medicine system; (3) completing health care service system at the primary level; (4) promoting uniform basic healthcare service; and (5) pushing reform pilots in public hospitals. A reform participant discloses that the proposal comprises a health reform framework and a complementary set of documents, with the latter detailing specific measures for implementation. (Click here for more - Chinese Language)
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.